
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Solid Dosage and Excipients
over 15 years ago
In the Spotlight April 2011over 15 years ago
Health-Reform Controversiesover 15 years ago
Biotechnology Loses Lead in Fundingover 15 years ago
Celebrity Couples to Disuniteover 15 years ago
Report From Chinaover 15 years ago
Scrutinizing the Subvisibleover 15 years ago
When Patience Pays Offover 15 years ago
Advancing Small-Molecule Synthesis




